FF/VI

DRUG5 trials

Sponsors

GlaxoSmithKline

Conditions

AsthmaPulmonary Disease, Chronic Obstructive

Phase 2

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

CompletedNCT01573624

GlaxoSmithKlineAsthma

Start: 2012-04-03End: 2013-02-04Updated: 2017-10-06

Phase 3

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01551758

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2012-03-13End: 2015-11-24Updated: 2017-05-31

Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT02729051

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2016-06-29End: 2017-05-23Updated: 2019-07-15

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

CompletedNCT04937387

GlaxoSmithKlineAsthma

Start: 2021-07-29End: 2024-08-05Updated: 2025-08-11

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

RecruitingNCT05757102

GlaxoSmithKlineAsthma

Start: 2023-04-25End: 2027-01-15Target: 292Updated: 2025-10-07

Related Papers

Pragmatic randomised controlled trials in COPD and asthma: how to guide clinical practice

BMJ Open Respiratory Research2022-09-013 citations

The impact of fluticasone furoate/vilanterol on healthcare resource utilisation in the Salford Lung Study in chronic obstructive pulmonary disease

Therapeutic Advances in Respiratory Disease2021-01-014 citations

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.

2018-01-2535 citations

P27 Deprivation in the copd salford lung study (sls) is associated with higher healthcare costs but does not moderate the main outcomes

2017-11-151 citations

P270 Identification of responder groups to fluticasone furoate/vilanterol (ff/vi) in the salford lung study in copd (sls copd) using a cluster analysis model

2017-11-15

P26 How does the salford lung study in copd (sls copd) patient population fit into the gold 2017 classification grid?

2017-11-15

P269 Describing adherence data in a clinical effectiveness trial: the salford lung study in copd (sls copd)

2017-11-15

Patient demographics and clinical characteristics in the UK Salford Lung Study (SLS COPD) and the European ACCESS study

2017-09-012 citations

Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice

New England Journal of Medicine2016-09-04191 citations

LATE-BREAKING ABSTRACT: Effect of fluticasone furoate (FF)/vilanterol (VI) on the rate of COPD exacerbations in everyday clinical practice: Results of the COPD Salford lung study (SLS)

2016-09-011 citations

The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease.

2015-09-0430 citations

Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma.

2015-07-168 citations

The effect of fluticasone furoate/umeclidinium in adult patients with asthma: A randomized, dose-ranging study

Respiratory Medicine2014-10-0351 citations

Obtaining real-world evidence: the Salford Lung Study

Thorax2014-03-0678 citations